Výsledky vyhledávání - "Conrad Messam"

Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study

Autor: Conrad Messam, Boguslawa Karaszewska, Donald A. Richards, Rodryg Ramlau, Bhabita Mayer, Kirushna Kumar, Eric S. Winer, Yasser Mostafa Kamel, Frederic Forget, Brendan M. Johnson, Howard Safran, Lee Hartner

Publikováno v: Cancer Medicine

Preventing chemotherapy-induced thrombocytopenia could avoid chemotherapy dose reductions and delays. The safety and maximum tolerated dose of eltrombopag, an oral thrombopoietin receptor agonist, with gemcitabine-based therapy was evaluated. Patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed9941b914567d3388495e10b25eb555
https://doi.org/10.1002/cam4.326

Zobrazit plný text záznamu

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors

Autor: Conrad Messam, Rita Patwardhan, A. Kellum, Y. M. Mostafa Kamel, Agnieszka Jagiełło-Gruszfeld, I N Bondarenko

Publikováno v: Current Medical Research and Opinion. 26:2339-2346

Eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, has been shown to increase platelet counts in adults with chronic immune thrombocytopenia and chronic hepatitis C. This multicenter phase 2 study assessed the efficacy and safety of el

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99687f873956f6bf2ea4c3aaf1965787
https://doi.org/10.1185/03007995.2010.510051

Zobrazit plný text záznamu

Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study

Autor: Lee Hartner, Boguslawa Karaszewska, Yasser Mostafa Kamel, Frederic Forget, Conrad Messam, Eric S. Winer, Rodryg Ramlau, Bhabita Mayer, Howard Safran, Brendan M. Johnson, Donald A. Richards, Kirushna Kumar

Publikováno v: Journal of Clinical Oncology. 30:9117-9117

9117 Background: There are limited tx options for CIT. Epag, an oral, small molecule, thrombopoietin-receptor agonist that increases platelet (plt) production, is being explored for tx of CIT. Methods: This was the Ph I portion of a Ph I/II, blinded,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a9321f89b6de887511ca9089bf6d0795
https://doi.org/10.1200/jco.2012.30.15_suppl.9117

Zobrazit plný text záznamu

Thrombopoietin expression and effects of eltrombopag in prostate, breast, lung, and ovarian solid tumors

Autor: Kodandaram Pillarisetti, Conrad Messam, Y. M. Mostafa Kamel, Yuan Liu, Connie L. Erickson-Miller, Lone Ottesen, Jennifer Kirchner, Anne-Marie Martin

Publikováno v: Journal of Clinical Oncology. 28:e21084-e21084

e21084 Background: Eltrombopag is a novel, oral thrombopoietin receptor (TPO-R; MPL) agonist that interacts with the TPO-R on bone marrow progenitors to stimulate megakaryocyte production, thus inc...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4548f2484949dc20c2a49cd6949606b
https://doi.org/10.1200/jco.2010.28.15_suppl.e21084

Zobrazit plný text záznamu

Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines

Autor: Conrad Messam, Jennifer Kirchner, Yasser Mostafa Kamel, Yuan Liu, Lone Ottesen, Anne-Marie Martin, Connie L. Erickson-Miller, Kodandaram Pillarisetti

Publikováno v: Blood. 114:2409-2409

Abstract 2409 Poster Board II-386 Background: Eltrombopag (Promacta®) is a novel, oral thrombopoietin receptor (TpoR) agonist that interacts with the TpoR on bone marrow progenitors to stimulate megakaryocyte production, thus increasing platelet cou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c9416c477e72022e00f96ecadcf0679
https://doi.org/10.1182/blood.v114.22.2409.2409

Zobrazit plný text záznamu

Hepatobiliary (HB) safety of eltrombopag administered after carboplatin+paclitaxel (Carb+Pac) in patients (pts) with solid tumors

Autor: R. Rafi, Conrad Messam, A. Kellum, P. Giangiulio, I N Bondarenko, Y. M. Mostafa Kamel, Agnieszka Jagiełło-Gruszfeld

Publikováno v: Journal of Clinical Oncology. 27:e20667-e20667

e20667 Background: Eltrombopag is an oral, small molecule, non-peptide, TPO-receptor agonist studied for the treatment of thrombocytopenia (TCP) due to various causes, including chemotherapy (CT)-induced TCP and is approved for the treatment of chron

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44429a64fdcc7d8ba037632b43ac8771
https://doi.org/10.1200/jco.2009.27.15_suppl.e20667

Zobrazit plný text záznamu

Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors

Autor: Jennifer Kirchner, Kodandaram Pillarisetti, Connie L. Erickson-Miller, Conrad Messam, David J. Figueroa, Lone Ottesen, Yuan Liu, Anne-Marie Martin, Yasser Mostafa Kamel

Publikováno v: BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 405 (2012)

Background Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d5fb15904087f36bfae7e0d787bc78

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání